SG11201407995RA - Stabilized gp120 - Google Patents

Stabilized gp120

Info

Publication number
SG11201407995RA
SG11201407995RA SG11201407995RA SG11201407995RA SG11201407995RA SG 11201407995R A SG11201407995R A SG 11201407995RA SG 11201407995R A SG11201407995R A SG 11201407995RA SG 11201407995R A SG11201407995R A SG 11201407995RA SG 11201407995R A SG11201407995R A SG 11201407995RA
Authority
SG
Singapore
Prior art keywords
international
emeryville
diagnostics
novartis
novartis vaccines
Prior art date
Application number
SG11201407995RA
Other languages
English (en)
Inventor
Andrea Carfi
Antu Dey
Aemro Kassa
Indresh Srivastava
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201407995RA publication Critical patent/SG11201407995RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201407995RA 2012-06-18 2013-06-17 Stabilized gp120 SG11201407995RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661050P 2012-06-18 2012-06-18
PCT/EP2013/062553 WO2013189901A1 (en) 2012-06-18 2013-06-17 Stabilized gp120

Publications (1)

Publication Number Publication Date
SG11201407995RA true SG11201407995RA (en) 2015-01-29

Family

ID=48628698

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407995RA SG11201407995RA (en) 2012-06-18 2013-06-17 Stabilized gp120

Country Status (14)

Country Link
US (1) US20150183835A1 (enExample)
EP (1) EP2861249A1 (enExample)
JP (1) JP2015521592A (enExample)
KR (1) KR20150023735A (enExample)
CN (1) CN104619338A (enExample)
AU (1) AU2013279456A1 (enExample)
CA (1) CA2876762A1 (enExample)
IL (1) IL235898A0 (enExample)
IN (1) IN2014KN02740A (enExample)
MX (1) MX2014014682A (enExample)
RU (1) RU2015101081A (enExample)
SG (1) SG11201407995RA (enExample)
WO (1) WO2013189901A1 (enExample)
ZA (1) ZA201408840B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10400015B2 (en) 2014-09-04 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
RU2745373C2 (ru) * 2014-09-23 2021-03-24 БЁРИНГЕР ИНГЕЛЬХАЙМ ЭНИМАЛ ХЕЛТ ЮЭсЭй ИНК. Рекомбинантные вакцины от fmdv и их применение
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10808011B2 (en) 2016-03-09 2020-10-20 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant HIV-1 envelope proteins and their use
WO2018075989A1 (en) 2016-10-21 2018-04-26 Altor Bioscience Corporation Multimeric il-15-based molecules
US11136356B2 (en) 2017-10-16 2021-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
CN109851664A (zh) * 2017-11-30 2019-06-07 清华大学 一种基于抗体反向表位设计的蛋白质及其在制备抗艾滋病病毒疫苗中的应用
EP3810755A4 (en) 2018-06-19 2021-12-01 Nantcell, Inc. COMPOSITIONS AND METHODS OF TREATMENT FOR HIV
WO2021249013A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Vaccine compositions, methods, and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786488B1 (fr) * 1998-11-27 2003-04-25 Orstom Mutants de la gp120 et leurs applications biologiques
EP1198468A4 (en) * 1999-06-25 2003-07-30 Progenics Pharm Inc STABILIZED VIRAL ENVELOPE PROTEINS AND THEIR USE
BRPI0815743A2 (pt) * 2007-08-24 2015-02-18 Novartis Ag Proteínas hiv env com modificações no laço v3
CA2774636C (en) * 2009-09-25 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use

Also Published As

Publication number Publication date
RU2015101081A (ru) 2016-08-10
IL235898A0 (en) 2015-01-29
WO2013189901A1 (en) 2013-12-27
ZA201408840B (en) 2016-08-31
CN104619338A (zh) 2015-05-13
KR20150023735A (ko) 2015-03-05
JP2015521592A (ja) 2015-07-30
US20150183835A1 (en) 2015-07-02
AU2013279456A1 (en) 2014-12-18
MX2014014682A (es) 2015-03-04
IN2014KN02740A (enExample) 2015-05-08
EP2861249A1 (en) 2015-04-22
CA2876762A1 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
SG11201407995RA (en) Stabilized gp120
SG11201903908PA (en) Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
SG11201804398XA (en) Method for producing rna molecule compositions
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201806829TA (en) 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201807912SA (en) Vaccine against rsv
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201901206SA (en) Trimer stabilizing hiv envelope protein mutations
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201909011PA (en) Niraparib compositions
SG11201408037SA (en) Humanized anti-trka antibodies with amino acid substitutions
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201408396QA (en) Improved resid hydrotreating catalyst containing titania
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201900021PA (en) Methods and compositions for the treatment of cancer
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201907207UA (en) Pharmaceutical combinations comprising an anti-ly75 antibody
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same